Botswana Vitamin D Supplementation Study in HIV/AIDS
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02189902 |
Recruitment Status :
Completed
First Posted : July 15, 2014
Last Update Posted : July 15, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV | Dietary Supplement: 4000 IU/d D3 over 12 weeks Dietary Supplement: 7000 IU/d D3 over 12 weeks | Phase 3 |
Many people living with HIV/AIDS in African countries are vit D deficient or insufficient. Vit D deficiency in HIV/AIDS may be due to low dietary vit D intake, increased requirements, malabsorption, specific drug therapies (antiretrovirals, in particular), reduced outdoor physical activity, reduced vit D synthesis from UV light exposure in dark skin pigmented individuals, or unknown HIV-associated factors. Vit D deficiency likely contributes to abnormal immune status and increased inflammatory state, and to poor growth, bone, and muscle function, and may contribute to risk for tuberculosis (TB) infection. The goal is to determine the vit D supplementation dose that safely results in optimal serum 25D concentrations in HIV-infected children and adults living in Botswana.
To do this the investigators will test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement over a 12-week period in 60 children and adults with HIV/AIDS living in Botswana (5.0 to 50.9 yrs), to assess safety as determined by serum calcium and 25D concentrations and efficacy to replete vit D status as determined by achieving a minimum serum 25D concentration of 32 ng/mL (80 nmol/L).
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Botswana Vitamin D Supplementation Study in HIV/AIDS |
Study Start Date : | January 2012 |
Actual Primary Completion Date : | July 2012 |
Actual Study Completion Date : | July 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 4000 IU/d of D3 by mouth for 12 weeks
4000 IU/d of D3 by mouth for 12 weeks
|
Dietary Supplement: 4000 IU/d D3 over 12 weeks |
Experimental: 7000IU/d of D3 by mouth for 12 weeks
7000IU/d of D3 by mouth for 12 weeks
|
Dietary Supplement: 7000 IU/d D3 over 12 weeks |
- To test the efficacy of two oral doses (4000 vs 7000 IU/d) of cholecalciferol (D3) in 60 children and adults (5.0 to 50.9 y) with HIV/AIDS to replete vit D status (achieving a minimum serum 25D concentration of 32 ng/mL). [ Time Frame: 12 weeks ]To test two oral doses (4000 vs 7000 IU/d) of cholecalciferol (D3) over a 12-week period in 60 children and adults (5.0 to 50.9 y) with HIV/AIDS to assess 25D concentrations and efficacy to replete vit D status as determined by achieving a minimum serum 25D concentration of 32 ng/mL.
- To test the safety of two oral doses (4000 vs 7000 IU/d) of cholecalciferol (D3) over a 12-week period in 60 children and adults (5.0 to 50.9 y) with HIV/AIDS as determined by serum calcium. [ Time Frame: 12 weeks ]To test two oral doses (4000 vs 7000 IU/d) of cholecalciferol (D3) over a 12-week period in 60 children and adults (5.0 to 50.9 y) with HIV/AIDS to assess safety as determined by serum calcium.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 5 Years to 51 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV infection
- Ages 5.0 to 50.9 y
- In usual state of good health
- Subject and/or family commitment to the 12-week study
Exclusion Criteria:
- Other chronic health conditions unrelated to HIV/AIDS that may affect nutritional status
- Use of vit D supplementation above 400 IU/d

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02189902
Botswana | |
Princess Marina Hospital | |
Gaborone, Botswana, 0000 |
Principal Investigator: | Virginia Stallings, MD | Children's Hospital of Philadelphia |
Responsible Party: | Virginia Stallings, Professor of Pediatrics, Children's Hospital of Philadelphia |
ClinicalTrials.gov Identifier: | NCT02189902 |
Other Study ID Numbers: |
812323 |
First Posted: | July 15, 2014 Key Record Dates |
Last Update Posted: | July 15, 2014 |
Last Verified: | July 2014 |
Vitamin D |
Acquired Immunodeficiency Syndrome HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases |